N-glycolylneuraminic acid-containing GM3 ganglioside (NeuGcGM3) (NeuGcGM3)

N-glycolylneuraminic acid-containing GM3 ganglioside (NeuGcGM3) is a sialic acid-containing glycosphingolipid that serves as a highly specific tumor-associated carbohydrate antigen (TACA). While prevalent in various human malignancies such as non-small cell lung cancer and melanoma, it is virtually absent in normal human tissues due to a functional deletion in the CMAH gene, which prevents the endogenous synthesis of N-glycolylneuraminic acid (Chou et al., 1998; Labrada et al., 2018). This target is often presented to the immune system via Very Small Size Proteoliposomes (VSSP) derived from Neisseria meningitidis, which act as a potent adjuvant to overcome natural tolerance and the low immunogenicity of carbohydrate structures (Mesa et al., 2004). By embedding NeuGcGM3 into these proteoliposomes, the formulation promotes the maturation of dendritic cells and shifts the immune environment toward a Th1-mediated anti-tumor response. Clinical interventions targeting NeuGcGM3, including the anti-idiotype vaccine Racotumomab and the NeuGcGM3/VSSP vaccine, have demonstrated the ability to elicit specific immune responses and improve survival outcomes in maintenance therapy settings for advanced solid tumors (Vázquez et al., 2012; Guthmann et al., 2006).

Other names

NGcGM3N-glycolyl-GM3Neu5GcGM3NGcGM3/VSSPTumor-associated ganglioside NeuGcGM3

The target is a tumor-associated carbohydrate antigen. Therapeutic strategies like the NeuGcGM3/VSSP vaccine utilize very small size proteoliposomes (VSSP) as an adjuvant to present the poorly immunogenic ganglioside to the immune system, thereby activating dendritic cells and inducing a Th1-polarized immune response (Mesa et al., 2004). Anti-idiotype antibodies such as Racotumomab mimic the NeuGcGM3 structure to trigger a specific humoral and cellular immune response against tumor cells expressing the ganglioside (Vázquez et al., 2012).